8/7/2019 GLAXO SMITHLINE

1/3

GLAXO SMITHLINE

GlaxoSmithKline Pharmaceuticals Ltd (GSK India) has its roots dating back to when itestablished in the year 1924. GSK is one of the oldest and leading research-based

healthcare and pharmaceutical company. The company's product assortment includes

prescription medicines and vaccines. The prescription medicines range across therapeuticareas such as anti-infectives, dermatology, gynaecology, diabetes, cardiovascular disease

and respiratory diseases. The company is the market leader in most of the therapeutic

categories in which it operates and has six products in the top 50 brands. GSK also offersa range of vaccines, for the prevention of hepatitis A, hepatitis B, invasive disease caused

by H, influenzae, chickenpox, diphtheria, pertussis, tetanus and others. Vaccines division

is ranked first in a fast-growing vaccines market.

GSK has two manufacturing units in India, located at Nashik and Thane as well as a

clinical development centre in Bangalore. The state of art plant at Nashik makes

formulations while bulk drugs are manufactured at Thane. During the year 1956, the

primary production of vaccines begins at Worli. In 1960's the Infant foods manufacturedat milk drying plant at Aligarh was came to existence and also manufacturing facility for

pharmaceuticals opened in Mumbai. After a year in 1961,Vitamin A and betamethasonemanufactured at new plant at Thane using imported raw materials. The company

registered as a limited company in the year 1968 and the Animal health products were

introduced in the same year. The Research & development laboratory was built at Thane

in the year 1971 and the company relocated the SmithKline & French plant from Mumbaito Bangalore. The Nashik factory was commissioned during the period of 1983.

SmithKline & Beecham becomes a public limited company under the new name of

Eskayef Limited in the year 1984 and one new Plant was sets up in Mysore formanufacture of bulk drugs. In 1985, the company's second basic drugs factory was

inaugurated at Ankleshwar, Gujarat.

Joint venture projects Vegepro Foods and Feeds Limited and K G Gluco Biols were

launched in the year 1986. The company's name was changed to Glindia Limited in 1987.

Production of bulk drug Ranitidine was commenced at Ankleshwar in the year 1988 andin the same year a joint venture project with Hindustan Foods Limited was made for the

manufacture of extruded foods at Usgao, Goa. During the period of 1989, commenced its

Zinetac production at Nashik and again the company's name were changed from Glindia

Limited to Glaxo India Limited. The production of the bulk drug, cephalexin wascommenced at Ankleshwar and the salbutamol inhalers at Nashik in the year 1990. Glaxo

rated amongst the first five of India's most respected companies (4th place), in a survey

by Businessworld magazine. An agreement was signed with the Council of Scientific andIndustrial Research (CSIR) during 1991. In the year 1992, the company sold its trade

investments in Vegepro and Feeds Limited, subsequently in the next year (1993) sold its

investment in Hindustan Foods Limited and Dempo Dairy Industries Limited. Cetzine, asecond-generation anti-histamine and research product of UCB Pharma (Belgium) was

launched under a co-marketing agreement. In the same year Glaxo received recognition

from the Ministry of Commerce as an export house. The company sold its Family

Products Division in the year 1994 to H J Heinz for a sum of Rs 210 crores. The Mysore

8/7/2019 GLAXO SMITHLINE

2/3

plant received ISO 9002 certification and the new Iodex plant was inaugurated in

Bangalore. Government approved state-of-the-art Pharmacy Research & Development

Centre (PR&D) inaugurated at Thane in the year 1995 to cater to the unmet medicalneeds and to exploit local commercial opportunities.

Glaxo acquired Biddle Sawyer Group of Companies in the year 1998, which wasstruggled in the year before. Gramin Arogya Vikas Sanstha - a rural development

programme initiated in Nashik. During 1999, Glaxo India completed it 75 years of

operations in India. During the year 2000, Agrivet Farm Care (AFC) tied up with Merial,the world's largest Animal Health Company, to market poultry vaccines. The company

ranked 6th in 'Business Today' - Stern Stewart & Co. listing of India's best Wealth

Creator Companies and also the launched Seretide for Asthma. The Merger of

SmithKline Beecham Pharmaceuticals (India) Limited into Glaxo India Limited wascompleted and the name of the company was changed to the present name

GlaxoSmithKline Pharmaceuticals Limited in India. Businessworld and the Indian

Market Research Bureau (IMRB) named GlaxoSmithKline as India's most respected

Pharmaceutical Company in a survey in the year 2003 and launched Cetzine (Cetirizine;anti-histamine), Zimig (terbinafine; anti-infective), CCM (calcium citrate maleate;

nutritional), Cobadex CZS (multivitamin with trace elements).

In the year 2004, the company launched Priorix (measles, mumps, rubella vaccine) and

the 'Augmentin' becomes the No. 1 pharmaceutical brand, as rated by IMS. The

foundation stone laid for GSK vaccines plant at Nashik in the year 2005. Launched oralcontraceptives: Elogen (desogestrel and ethinylestradiol) and Zerogen (progesterone only

pill) and has the company entered into the diabetes therapeutic segment with the launch

of Windia (rosiglitazone) and Windamet (rosiglitazone and metformin). During theperiod of 2006, the company's Augmentin grows to a Rs. 100 crore brand. In-licensing

alliance was made with Eisai Pharmaceuticals, Japan and launched Parit (rabeprazole;

gastrointestinal therapy area). GlaxoSmithKline divests its Agrivet Farm Care (AFC)animal health business in the year. In 2007, the company launched Carzec (carvedilol)

and Zemetril (cefprozil). The Company has opened its new Medicinal Chemistry

Laboratory at its research and development facility in Singapore's biomedical researchhub, Biopolis in March of the year 2007. After the exit from animal health business, GSK

Pharma has divested its other peripheral business of fine chemicals as well in the same

year 2007 with consideration of Rs.240 crores on slump sale basis to Thermo Electron

LLS India Private Ltd. The company launched two of its new innovative Diphtheria,Tetanus and acellular Pertussis (DTP) vaccines, such as Boostrix and Infanrix in January

of the year 2008. Also the company in well positioned to launch the breast cancer drug,

Tykerb and the rotavirus vaccine, Rotarix during the year 2008.

GlaxoSmithKline Pharmaceuticals Limited, a subsidiary of GlaxoSmithKline plc is

consecutively moving with mission to improve the quality of life by enabling people todo more, feel better and live longer. This mission drives the company to make a real

difference to the lives of millions of people with commitment to effective healthcare

solutions. With opportunities in India opening up, GSK India is aligning itself with the

parent company in areas such as clinical trials, clinical data management, global pack

8/7/2019 GLAXO SMITHLINE

3/3

management, sourcing raw material and support for business processes including

analytics.